These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18573805)

  • 1. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
    Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
    Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
    Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
    Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
    Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
    Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
    Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
    Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
    Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.